PXL/HO/Cir-095/2023-24 Date: 09.02.2024
Subject: Request for suggestions/inputs on Market Access Issues in China and Hong Kong
NEA region is the largest Generic market. It houses China, the largest manufacturer of generics as well as APIs, drug intermediates globally. This region's generic market is forecasted to grow by 11.78% taking the market from $ 132.29 billion to $ 147.88 billion in 2023.
India's exports during the year 2022-23 to the NEA region have reached USD 864 mn with a growth rate of 7.51% contributing to 3.40% of total exports, despite many challenges.
The export of Pharmaceuticals from India to Hong Kong and China have seen a slowdown during April –Dec.2024 negatively by 8% and we therefore request member exporters to share the reasons for slowdown in exports and also the market access issues to take appropriate measures for increasing exports.
Companies are requested to kindly submit the Market Impediments being faced by them while exporting to the above-mentioned countries in the Google Form.
If no information is available, kindly fill in the blank with N/A to go to the next section. Given the time bound nature of this activity, it is requested to kindly complete the form by 11.Feb.2024.